Recent 8-K filings for APVO

• May 27, 2026, 4:05 PM ET other material materiality 0.75 positive item 1.01item 3.02item 7.01item 9.01

  Aptevo (APVO) partners with Niowave for radiopharma development; Niowave takes 7.9% equity stake

  50/50 strategic collaboration to develop up to three radiopharmaceutical oncology programs using Aptevo's multispecific platforms and Niowave's radioisotopes.

• May 13, 2026, 4:05 PM ET other material materiality 0.65 positive item 2.02item 9.01

  Aptevo reports 81% remission rate for mipletamig in frontline AML; $60M equity line secured

  Mipletamig plus venetoclax/azacitidine: 87% clinical benefit rate, 81% CR/CRi, 65% CR in 31 evaluable patients; no CRS.

• May 6, 2026, 7:59 PM ET other material materiality 0.90 positive item 8.01item 9.01

  Aptevo Reports 87% Clinical Benefit Rate and 81% Remission in Frontline AML Trial RAINIER

  Across 31 evaluable frontline AML patients, mipletamig combo showed 87% clinical benefit rate and 81% remission (CR/CRi), outperforming VIALE-A benchmark of 66.4%.

• March 26, 2026, 7:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01 ◈ Earnings Releases

  Aptevo FY2025 net loss $26M, cash $21.6M; mipletamig 86% CBR in AML; CEO transition

  Mipletamig triplet in 28 frontline AML patients: 86% CBR, 79% CR/CRi, no CRS observed.

• March 11, 2026, 7:59 PM ET other material materiality 0.75 positive item 8.01item 9.01

  Aptevo reports 86% clinical benefit rate for mipletamig combo in frontline AML, zero CRS

  Mipletamig + venetoclax + azacitidine showed 86% clinical benefit rate (CR/CRi/PR) in 28 evaluable frontline AML patients.

• February 3, 2026, 6:59 PM ET leadership materiality 0.75 positive item 5.02item 9.01

  Marvin White retires as Aptevo CEO; COO Jeff Lamothe named successor effective April 1, 2026

  White to become Executive Chair; Lamothe promoted from COO to President and CEO and appointed to Board.

• January 9, 2026, 6:59 PM ET other material materiality 0.65 positive item 1.01item 3.02item 8.01item 9.01 ◈ Material Agreements

  Aptevo secures $60M equity line with Yorkville, extends funding runway into 2029

  Enters $60M Standby Equity Purchase Agreement with Yorkville; minimal fees, no warrants.

• December 29, 2025, 6:59 PM ET other materiality 0.60 negative item 5.03item 9.01 ◈ Governance Changes

  Aptevo Therapeutics files 1-for-18 reverse stock split effective Dec 29, 2025

  Reverse split ratio 1-for-18 approved by board Dec 17; effective Dec 29 at 5:01 PM ET.

• December 9, 2025, 6:59 PM ET other material materiality 0.75 positive item 8.01item 9.01

  Aptevo reports mipletamig 93% ORR, zero CRS in frontline AML Phase 1b/2 trial at ASH 2025

  100% of patients free of cytokine release syndrome (CRS) across cohorts 1-3.

• November 6, 2025, 6:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Aptevo reports 89% remission in frontline AML with mipletamig; Q3 net loss $7.5M

  89% of evaluable frontline AML patients achieved remission (CR+CRi) across two trials of mipletamig; no cytokine release syndrome observed.

• September 16, 2025, 7:59 PM ET other material materiality 0.80 positive item 8.01item 9.01

  Aptevo reports 100% remission rate in Cohort 3 of Phase 1b/2 RAINIER trial for mipletamig in AML

  100% remission rate (CR/CRi) in Cohort 3 with mipletamig + venetoclax + azacitidine for newly diagnosed AML unfit for intensive chemo.

• September 4, 2025, 7:59 PM ET other material materiality 0.60 positive item 8.01item 9.01

  Aptevo expands oncology pipeline with two new trispecific candidates APVO452 and APVO451

  Filed provisional patents for APVO452 (PSMA x CD3 x CD40) targeting prostate cancer and APVO451 (Nectin-4 x CD3 x CD40) for multiple solid tumors.

• August 11, 2025, 7:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01

  Aptevo Q2 net loss $6.2M; mipletamig 85% remission in AML; pipeline expands with APVO455

  Net loss $6.2M for Q2 2025; cash $9.4M as of June 30, 2025.

• June 30, 2025, 7:59 PM ET other material materiality 0.80 positive item 8.01

  Aptevo raises $15.9M in Q2 equity offerings, believes it regains Nasdaq compliance on stockholders' equity

  Raised approx. $15.9M via four equity transactions: April 4 ($2.1M), April 22 ($2.0M), June 20 ($8.0M), and ATM facility ($3.8M).

• June 20, 2025, 7:59 PM ET other material materiality 0.85 positive item 1.01item 8.01item 9.01

  Aptevo raises $8M, reports 85% remission for mipletamig in AML, adds APVO455

  Gross proceeds of ~$8M from registered direct offering of 2.465M shares/pre-funded warrants and 12.325M common warrants at $3.25/unit.

• June 17, 2025, 7:59 PM ET other material materiality 0.65 neutral item 1.01item 3.02item 9.01

  Aptevo Therapeutics enters $25M standby equity purchase agreement with Yorkville

  Up to $25M in common stock may be sold to YA II PN over 36 months at 96% of lowest 3-day VWAP.

• May 23, 2025, 7:59 PM ET other material materiality 0.60 negative item 5.03item 9.01

  Aptevo Therapeutics effects 1-for-20 reverse stock split effective May 23, 2025

  Stockholders approved reverse split 1:6 to 1:20 at May 14 special meeting; board chose 1:20 on May 21.

• May 22, 2025, 7:59 PM ET regulatory materiality 0.80 negative item 3.01item 8.01item 9.01

  Aptevo receives Nasdaq delisting notice for equity deficiency; announces 1-for-20 reverse split

  Nasdaq notified Aptevo of non-compliance with $2.5M stockholders' equity rule; deficit of $1.473M as of March 31, 2025.

• May 15, 2025, 7:59 PM ET other material materiality 0.75 positive item 2.02item 9.01

  Aptevo reports 90% remission rate in frontline AML with mipletamig triplet; no CRS

  9 of 10 frontline AML patients achieved remission with mipletamig + venetoclax + azacitidine across two trials.

• April 29, 2025, 7:59 PM ET other material materiality 0.60 neutral item 8.01item 9.01

  Aptevo files prospectus supplement to sell up to $3.17M in common stock via ATM

  ATM offering of up to $3,167,548 in common stock under sales agreement with Roth Capital Partners.

• April 28, 2025, 7:59 PM ET other material materiality 0.60 neutral item 1.01item 2.02item 8.01item 9.01

  Aptevo enters ATM equity facility up to $2.96M; reports preliminary Q1 cash of $2.1M

  Entered ATM sales agreement with Roth Capital to sell up to $2,959,952 in common stock; Roth receives 3.0% commission.

• April 4, 2025, 7:59 PM ET other material materiality 0.70 neutral item 1.01item 3.02item 8.01item 9.01

  Aptevo raises $2.1M in registered direct offering and private placement; existing warrants amended

  Sold 1,764,710 shares of common stock and warrants to purchase up to 3,529,420 shares at $1.19/unit.

• March 20, 2025, 7:59 PM ET other material materiality 0.85 positive item 7.01item 8.01item 9.01

  Two additional AML patients achieve remission in Cohort 2 of RAINIER trial; 90% response rate

  Two additional AML patients in Cohort 2 of RAINIER trial achieved remission within 30 days of treatment.

• February 14, 2025, 6:59 PM ET other material materiality 0.70 positive item 2.02item 9.01

  Aptevo reports 100% remission in Cohort 1 of RAINIER AML trial; 59% stable disease rate in ALG.APV-527 trial

  Mipletamig RAINIER Cohort 1: 100% of patients achieved remission within 30 days, including one MRD-negative status.

• December 12, 2024, 6:59 PM ET other material materiality 0.70 positive item 8.01item 9.01

  Aptevo: 100% remission in Cohort 1 of mipletamig frontline AML trial; 2 of 3 patients MRD-negative

  100% of patients (3/3) achieved remission within 30 days in Cohort 1 of RAINIER Phase 1b trial.

• December 12, 2024, 6:59 PM ET other material materiality 0.70 neutral item 1.01item 3.02item 9.01

  Aptevo raises up to $6.2M via warrant exercise inducement; issues new warrants at $9.53

  Holders exercise up to 823,544 existing warrants at $7.50/share for ~$6.2M gross proceeds.

• November 20, 2024, 6:59 PM ET other material materiality 0.70 positive item 8.01item 9.01

  Aptevo reports first RAINIER trial patient achieved 90% leukemic blast reduction in 30 days

  First patient in Phase 1b/2 RAINIER trial achieved 90% reduction in leukemic blasts within first 30 days.

• November 7, 2024, 6:59 PM ET earnings materiality 0.60 neutral item 2.02item 9.01

  Aptevo Q3 net loss $5.1M; cash $7.8M; initiates RAINIER trial for AML

  Net loss of $5.1M ($0.48 per share) in Q3 2024 vs $6.3M ($22.16) in Q3 2023.

• October 25, 2024, 7:59 PM ET other material materiality 0.70 negative item 5.07

  Aptevo shareholders approve reverse stock split (1:5–1:37) and dilutive stock issuance

  Stock issuance and warrant proposal passed (593,301 For, 412,901 Against, 5,355 Abstain).

• September 18, 2024, 7:59 PM ET other material materiality 0.65 neutral item 1.01item 8.01item 9.01

  Aptevo raises $3.0M via registered direct offering of stock and warrants at $0.33/share

  Issued 9,090,910 shares or pre-funded warrants plus warrants for up to 18,181,820 shares at $0.33 per unit.

• September 16, 2024, 7:59 PM ET other material materiality 0.60 positive item 8.01item 9.01

  Aptevo/Alligator Phase 1 ALG.APV-527 trial: 60% stable disease, 11+ month duration in breast cancer

  Phase 1 data presented at ESMO: 9 of 15 evaluable patients (60%) achieved stable disease across solid tumors.

• August 8, 2024, 7:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01

  Aptevo posts Q2 net loss $5.9M, cash $8.1M; APVO436 Phase 1b/2 trial to begin

  Net loss of $5.9M ($1.67/sh) vs $7.9M ($53.95/sh) in Q2 2023; R&D spend down 33% to $3.6M.

• July 1, 2024, 7:59 PM ET other material materiality 0.60 neutral item 1.01item 8.01item 9.01

  Aptevo raises ~$2.75M gross in registered direct offering at $0.515/share

  Offering of 5,339,806 shares (or pre-funded warrants) and 10,679,612 common warrants at $0.515/share; net proceeds ~$2.3M.

• July 1, 2024, 7:59 PM ET regulatory materiality 0.75 negative item 3.01

  Aptevo receives Nasdaq deficiency notice for bid price below $1.00; 180-day cure period until Dec 23, 2024

  Received Nasdaq Staff letter on June 25, 2024, for failure to meet minimum $1.00 bid price requirement.

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.90 · Median 0.65 · Most common event other_material

21 positive 6 negative 23 neutral

source · APVO on sec.gov